The aim of this study was to analyze the function and expression of tachykinins, tachykinin receptors, and neprilysin (NEP) in the mouse uterus. A previous study showed that the uterotonic effects of substance P (SP), neurokinin A (NKA), and neurokinin B (NKB) in estrogen-treated mice were mainly mediated by the tachykinin NK 1 receptor. In the present work, further contractility studies were undertaken to determine the nature of the receptors mediating responses to tachykinins in uteri of late pregnant mice. Endpoint and real-time quantitative RT-PCR were used to analyze the expression of the genes that encode the tachykinins SP/NKA, NKB, and hemokinin-1 (HK-1) (Tac1, Tac2, and Tac4); and the genes that encode tachykinin NK 1 (Tacr1), NK 2 (Tacr2), and NK 3 (Tacr3) receptors in uteri from pregnant and nonpregnant mice. The data show that the mRNAs of tachykinins (particularly NKB and HK-1), tachykinin receptors, and NEP are locally expressed in the mouse uterus, and their expression changes during the estrous cycle and during pregnancy. The tachykinin NK 1 receptor is the predominant tachykinin receptor in the nonpregnant and early pregnant mouse and may mediate tachykinin-induced uterine contractions in the nonpregnant mouse. The tachykinin NK 2 receptor is predominant in the late pregnant mouse and is the main receptor mediating uterotonic responses to tachykinins at late pregnancy. The tachykinin NK 3 receptor is expressed in considerable amounts only in uteri from nonpregnant diestrous animals, and its physiological significance remains to be clarified.
INTRODUCTION
Tachykinins are a family of biologically active peptides that includes substance P (SP), neurokinin A (NKA), neurokinin B (NKB), and the more recently described peptide hemokinin-1 (HK-1) [1] [2] [3] [4] [5] [6] [7] and its human orthologs, endokinin A and B (EKA and EKB) [8] . These peptides are widely distributed throughout the periphery within capsaicin-sensitive primary afferent neurons and non-neuronal cells [1, 8, 9] and produce a diverse range of biological effects that are mediated through three receptors, termed NK 1 , NK 2 , and NK 3 [10, 11] .
Accumulating data suggest that tachykinins may be involved in the regulation of reproductive functions [12] [13] [14] . In the female reproductive tract, the presence of tachykininlike immunoreactivity has been demonstrated in numerous species [15] [16] [17] [18] [19] [20] [21] . Recent studies have also shown that the genes that encode NKB, HK-1, and EKB are expressed in the uterus [8, [22] [23] [24] . We have reported previously that tachykinins produce a direct contractile effect on uterine smooth muscle from rats [22, [25] [26] [27] [28] [29] [30] [31] [32] [33] , humans [24, 34, 35] , and mice [19, 36] . These functional studies together with molecular studies indicate that the NK 2 receptor is the predominant receptor involved in mediating tachykinin-induced contractions in uteri from both pregnant and nonpregnant rats and humans [19, 24, 27, [32] [33] [34] [35] 37 ]. In contrast, the NK 1 receptor seems predominant in mediating uterine contractility in the nonpregnant, estrogen-primed mouse [36] .
The aim of the present study was to examine the contractile effect and the expression of the tachykininergic system in uteri from nonpregnant and pregnant mice. Functional studies were undertaken to characterize the tachykinin receptors involved in mediating myometrial contractility and the influence of peptidase inhibition on tachykinin responses in the mouse uterus. In addition, endpoint and real-time quantitative reverse transcription (RT)-polymerase chain reaction (PCR) were used to analyze the expression of the genes that encode SP/NKA (Tac1), NKB (Tac2), and HK-1 (Tac4), respectively; and the genes encoding the tachykinin NK 1 (Tacr1), NK 2 (Tacr2), and NK 3 (Tacr3) receptors. We also studied the expression of Mme, the gene that encodes neprilysin (NEP), which is the key enzyme involved in tachykinin metabolism in the mammalian uterus.
A preliminary account of some of the findings of this study was communicated to the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists [38, 39] .
MATERIALS AND METHODS

Animals and Tissue Preparation
Prior ethical approval for these studies was obtained from the Monash University Standing Committee on Ethics in Animal Experimentation (Australia) and the Ethics Committee of Consejo Superior de Investigaciones Científicas (Spain).
Female, nonpregnant (20-25 g) BalbC mice were purchased from Charles River Laboratories (Barcelona, Spain) or bred in the Monash University Animal House. Mice were housed in the corresponding Departmental Animal House in an air conditioned room at 22ЊC under controlled lighting (12L:12D), with free access to food and water. Female mice were mated with a male overnight to induce pregnancy. Vaginal smears were checked to determine the stage of the estrous cycle in the untreated nonpregnant animals and to confirm pregnancy in mated females. The day on which a vaginal plug was observed was defined as Day 1 of gestation. Mice were killed by decapitation following exposure to CO 2 , and the uterine horns were rapidly removed and trimmed of surrounding connective tissue. For contractility studies, uteri were obtained from 1) virgin mice treated 24 h before with estradiol cypionate (200 g/kg, s.c.) and 2) from Day 17 pregnant mice. Uterine horns from nonpregnant animals were opened along the mesometrial border and transected medially to provide four preparations per animal. Uterine horns from Day 17 pregnant mice were similarly opened, and fetuses removed and decapitated before uteri were excised, providing up to eight preparations per mouse. For molecular studies, samples from the middle section of the uterus were obtained from 1) virgin mice in the estrous or diestrous stage of the ovarian cycle, 2) virgin mice treated 24 h before with a single injection of estradiol benzoate (200 g/kg, s.c.), and 3) pregnant mice on Day 5 or Day 17 of an average 19-day gestation period. Samples of brain cortex used as a positive control of amplification of the target genes were obtained from the same mice. Tissues were quickly frozen in liquid nitrogen and stored at Ϫ80ЊC until use.
Functional Studies
Uterine preparations from nonpregnant estrogen-treated or Day 17 pregnant mice (10 mm ϫ 5 mm; mean weight ϭ 32.7 Ϯ 2.2 mg, n ϭ 32 preparations) were mounted in 5-ml siliconized organ baths containing a physiological salt solution (PSS) of the following composition (mM): NaCl, 118.0; KCl, 4.7; MgSO 4 · 7H 2 0, 1.1; KH 2 PO 4 , 1.18; NaHCO 3 , 25.0; glucose, 11.66; CaCl 2 · 2H 2 O, 1.9; warmed to 37ЊC. Preparations were bubbled continuously with carbogen gas (95% O 2 , 5% CO 2 ) to maintain a pH of 7.4. Contractile force produced by the longitudinally oriented smooth muscle fibers was recorded by a Grass FT03 force transducer connected to a MacLab data acquisition system.
Agonist Log Concentration-Response Curves
Uterine preparations were set up under an initial resting force of 1 g (nonpregnant) or 2 g (pregnant) and allowed to equilibrate for 2 h with the PSS replaced every 20 min. Following the equilibration period, discrete concentration-response curves were constructed to SP, NKA, NKB, the NK 1 receptor-selective agonist [Sar 9 Met(O 2 ) 11 ]SP, and the NK 2 receptor-selective agonist [Lys 5 MeLeu 9 Nle 10 ]NKA(4-10) (0.1 nM to 1 M). Agonists remained in contact with the tissue for 5 min; the tissue was then washed and a higher concentration of agonist added 15 min later. At the conclusion of the experiment, methacholine (MCh, 10 M), used as a negative control, was applied for 5 min and washed out, and 15 min later the tissues were exposed to a modified PSS (KPSS) in which 40 mM KCl replaced 40 mM NaCl. 
Antagonist Studies
Peptidase Inhibitor Studies
In a subset of experiments log concentration-response curves to SP and NKA were obtained in the absence and presence of the peptidase inhibitors thiorphan (3 M), captopril (10 M), and bestatin (10 M). Peptidase inhibitors were present throughout the experiment, and were replaced each time the bath was washed out.
Molecular Studies
RNA Extraction and Reverse Transcription. Total RNA from approximately 20 mg of mouse uterine tissue or brain cortex was isolated using the method described by Chomczynski and Sacchi [40] . Residual genomic DNA was removed by incubating the RNA samples with RNase-free, fast protein liquid chromatography pure DNase I (Amersham Biosciences, Essex, U.K) and RNasin (Promega Corp., Madison, WI). The quantity of total RNA was determined by spectrophotometric measurement at 260 nM. DNase-treated total RNA (2 g) was reverse transcribed using a firststrand cDNA synthesis kit (Amersham Biosciences) and the resulting samples were diluted to 400 l with DNase-free water.
PCR Primers
Specific oligonucleotide primers were used to amplify Tac1, Tac2, Tac4, Tacr1, Tacr2, Tacr3, Mme, and ␤-actin in cDNAs from nonpregnant mice in the estrous or diestrous stage of the estrous cycle; nonpregnant, estrogen-treated mice; and Day 5 and Day 17 pregnant mice (five mice per group). The primer pairs were designed with the analysis software Primer 3 [41] and used for both endpoint and real-time PCR. Amplification of the ␤-actin gene transcript was used as an internal control of RT-PCR reactions among the samples. The structures of the primers used are shown in Table 1 . All primers were synthesized and purified by Sigma Genosys (Cambridge, U.K.).
Endpoint PCR
An endpoint PCR assay was used to detect the mRNAs of preprotachykinins, tachykinin receptors, and neprilysin and to establish the identity of the amplified products. A 3-l aliquot of the resulting cDNA was used as a template for PCR amplification using a DNA thermal cycler (MJ Research, Watertown, MA). PCR mixes contained 0.2 mol primers, 1.5 U Taq polymerase (Amersham Biosciences), the buffer supplied, 2.5 mmol MgCl 2 , and 200 mol dNTPs and cDNA in 25 l. After a hot start (2 min at 94ЊC), the parameters used for PCR amplification were 10 sec at 94ЊC; 20 sec at 60ЊC, and 30 sec at 72ЊC. These cycles were repeated 35 times for tachykinins, tachykinin receptors, and neprilysin; and 24 times for ␤-actin. Serial half dilutions of cDNA were amplified at the indicated number of cycles for each target gene and ␤-actin to ensure analysis of products in the linear range of amplification. The PCR products were separated by gel electrophoresis, stained with ethidium bromide, and visual- ized and photographed under a UV transilluminator (Spectronics Corp., Westbury, NY). Messenger RNA expression for all target genes and ␤-actin was analyzed on each tissue, and each PCR experiment was carried out in triplicate. Amplicon sizes were verified by comparison with a DNA mass ladder, and the identity of each PCR product was established by DNA sequence analysis as previously described [32] . No PCR product was detectable when the samples were amplified without the RT step, suggesting that genomic DNA contamination was eliminated by DNase treatment. Similarly, no products were detected when the RT-PCR steps were carried out with no added RNA, indicating that all reagents were free of target sequence contamination.
Real-Time PCR
Real-time PCR was used to quantify the expression of Tac2, Tac4, Tacr1, Tacr2, and Mme in the mouse uterus using the iCycler iQ realtime detection system from Bio-Rad Laboratories (Hercules, CA) and SYBR green (Molecular Probes, Leiden, The Netherlands) as previously described [24] . The PCR reaction mixture was identical to that used in the endpoint PCR assay, adding SYBR green I dye (1:75 000 dilution of the 10 000ϫ stock solution). The reactions were performed in 96-well thinwall PCR plates covered with a sheet of optical-quality sealing film. Thermal cycling conditions were the same as those described for endpoint assays, and fluorescence measurements were recorded during each extension step. For all samples, ␤-actin was used as the endogenous control for normalization of initial RNA levels. Control samples without the RT step and with no added RNA were also included with each plate to detect any possible contamination.
At the end of each PCR run, the data were automatically analyzed by the system, and an amplification plot was generated for each DNA sample. From each of these plots, the iCycler software calculates the threshold cycle (C T ), defined as the fractional cycle number at which the fluorescence reaches 10ϫ the standard deviation of the baseline. The fold expression or repression of the target gene relative to ␤-actin in each sample was then calculated by the formula 2 Ϫ⌬⌬C T , where ⌬C T ϭ C Ttarget gene Ϫ C T␤-actin and ⌬⌬C T ϭ ⌬C Ttest sample Ϫ ⌬C Tcontrol .
For each target gene, real-time PCR data from a uterine sample of a virgin mouse in estrus was arbitrarily chosen as control, and this sample was included in all PCR experiments to correct for possible interassay variations. The target gene mRNA:␤-actin mRNA ratio in the control sample was designated as 1. Three serial dilutions of cDNA template were prepared from each tissue, and each dilution was amplified in triplicate. The experimental approach was further validated by the observation that the differences between the C T for the target gene and ␤-actin remained essentially constant for each starting DNA amount.
Data Analysis
All values are expressed as the mean Ϯ SEM; except where otherwise stated, n represents the number of mice used.
Contractile responses to each agonist were measured as area under the force-time curve (g·s) for the 5-min period that the agonist remained in contact with the tissue. Spontaneous activity was subtracted from the data when observed at 2 h. Responses were then expressed as a percentage of the corresponding response to KPSS and presented as mean Ϯ SEM. To determine agonist potencies in the absence or presence of antagonists, mean log concentration-response curves were constructed using nonlinear regression analysis in GraphPad PRISM (version 3.0) to determine pD 2 values. When pairs of mean regression lines over the linear range of the log concentration-response curve were parallel, a potency ratio with 95% confidence limits was obtained as described previously. Shifts were considered significant when the 95% confidence limits did not include one.
Other statistical procedures used included one-way and two-way analysis of variance (ANOVA) followed by a Tukey or Student-NewmanKeuls pairwise test for multiple comparisons and Student unpaired t-tests to compare the means of two groups. These procedures were undertaken using SigmaStat (version 2.0) or GraphPad PRISM (version 3.0). Statistical significance was accepted when P Ͻ 0.05.
Drugs
The drugs used were bestatin (Sigma, St. 
RESULTS
Functional Studies
All preparations initially exhibited spontaneous activity, which subsided during the equilibration period. The mean response to KPSS in pregnant mice was 1020.2 Ϯ 67.6 g.s/5 min (n ϭ 32 preparations). The mean response to MCh was 78.0% Ϯ 2.6% of the response to KPSS. No significant differences in the mean responses to either MCh or KPSS were observed in experiments in which the potencies of tachykinin agonists was compared (one-way AN-OVA, P Ͼ 0.05).
Agonist Studies
All tachykinin peptides tested elicited contractile activity in the pregnant mouse uterus. ilar to that of NKA, which was significantly higher than that of [Sar 9 Met(O 2 ) 11 ]SP (Fig. 2B , one-way ANOVA, P Ͻ 0.05). 
Antagonist Studies
Peptidase Inhibitor Studies
In our previous study of the uterotonic effect of tachykinins in the nonpregnant, estrogen-primed mouse uterus [36] we included a cocktail of peptidase inhibitors comprising thiorphan (3 M), captopril (10 M), and bestatin (10 M). In the present study, we compared the effects of this cocktail on responses to SP and NKA in the nonpregnant estrogen-primed and Day 17 pregnant mouse myometrial preparations (Fig. 4) . Two-way ANOVAs showed that in tissues from estrogen-primed mice the responses to NKA were significantly larger in the presence of peptidase inhibitors (P Ͻ 0.05, df ϭ 144), whereas the responses to SP in the presence of peptidase inhibitors did not differ significantly from control (P Ͼ 0.05, df ϭ 128). In the pregnant mouse the responses to NKA (P Ͼ 0.05, df ϭ 72) and SP (P Ͼ 0.05, df ϭ 80) were not significantly different in the presence of the peptides inhibitor cocktail. The relative potencies of NKA and SP were unchanged from control data.
Molecular Studies
By using endpoint RT-PCR, we detected the presence of mRNA transcripts corresponding to the sizes expected for Tac2 (302 base pair; bp), Tac4 (186 bp), Tacr1 (223 bp), Tacr2 (251 bp), Tacr3 (272 bp), and Mme (255 bp). The identity of the amplified fragments was confirmed by DNA sequence analysis. The mRNA of Tac1 (364 bp), the gene that encodes SP and NKA, was absent or, in some uterine samples, present in trace amounts that were detectable only after amplification of higher amounts of cDNA. Figure 5 illustrates an example of an agarose gel showing RT-PCR products obtained by amplification of similar amounts of mouse uterine cDNA, as determined from the previous amplification of the ␤-actin sequence. As can be observed, there were marked variations among the levels of expression of the different target genes depending on the stage of the estrus cycle and the stage of gestation.
Real-time quantitative PCR was therefore used to compare the relative abundance of Tac2, Tac4, Tacr1, Tacr2, and Mme mRNAs among pregnant and nonpregnant mouse uteri. It was not possible to quantify the expression levels of Tac1 and Tacr3 due to the absence of the specific transcripts or, in the case of Tacr3, because quantifiable levels in uterine cDNA were present only in tissue from nonpregnant mice in diestrus.
A low expression of Tac2, the gene that encodes NKB, was detected in two of five nonpregnant mice in diestrous and in all assayed Day 5 and Day 17 pregnant mice (n ϭ 5). There was no detectable expression in uterine cDNA from estrogen-treated (data not shown) animals or from those in estrous (see Fig. 5 ). The highest mRNA levels were found in Day 5 pregnant mice (Fig. 6A) . Tac2 mRNA decreased by 38-fold in Day 17 pregnant mice, compared with those at Day 5 of pregnancy (Fig. 6A) .
The mRNA of Tac4, the gene that encodes HK-1, was present in all uteri assayed. The highest expression was observed in uteri from nonpregnant diestrous mice and from Day 5 pregnant mice (Fig. 6B) . Compared with mice in diestrus, Tac4 mRNA decreased by 2.6-fold in uteri from nonpregnant mice in estrus and by 10.2-fold in Day 17 pregnant mice (Fig. 6B) .
Tachykinin NK 1 receptor mRNA levels were similar in uteri from nonpregnant estrous, diestrous (Fig. 6C) , and estrogen-treated (data not shown) mice. Compared with its expression in estrous and diestrous mice, Tacr1 mRNA increased by approximately 2-fold on Day 5 of pregnancy and decreased by approximately 11-fold on Day 17 of pregnancy (Fig. 6C) .
The mRNA levels of the tachykinin NK 2 receptor in uteri from either nonpregnant or pregnant mice were low (see Fig. 5 ) and it was necessary to use a higher number of cycles (42 cycles) for real-time PCR detection. Tacr2 expression was slightly higher in pregnant compared with nonpregnant animals (Fig. 6D) . However, there were no significant differences between the mRNA levels in the different conditions assayed (P Ͼ 0.05; n ϭ 5 mice per group, one-way ANOVA; Fig. 6D ).
The mRNA of neprilysin was detected in all uteri assayed both from pregnant and nonpregnant mice. Among the genes assayed, the expression of NEP varied most among the different uterine samples. Thus, compared with nonpregnant mice in diestrus (n ϭ 5), Mme mRNA levels decreased by 14.5-fold in nonpregnant estrous mice (P Ͻ 0.01; n ϭ 5), by 4-fold in Day 5 pregnant mice (P Ͻ 0.05; n ϭ 5), and by 9-fold at Day 17 of pregnancy (P Ͻ 0.01; n ϭ 5), (Fig. 7) . The expression of neprilysin was similar in estrous mice and in Day 17 pregnant animals (P Ͼ 0.05, one-way ANOVA; Fig. 7 ).
DISCUSSION
The main findings of the present study demonstrate that pregnancy induced a change in the predominant tachykinin receptor type that mediates the contractile effects of tachykinins in the mouse uterus. This shift appears due in part to down-regulation of the expression of the tachykinin NK 1 receptor during late pregnancy. Furthermore, the mRNAs of the tachykinins NKB and HK-1, and the tachykinin receptors, are shown to be locally expressed in the mouse uterus with their expression levels changing during the estrous cycle and during pregnancy.
Several recent findings at both central [42, 43] and peripheral [12-14, 24, 33, 35, 44 ] levels argue for a role for tachykinins in the regulation of female reproductive function. Studies carried out with uteri from humans and rats have shown the presence of all mammalian tachykinins, their receptors, and the tachykinin-metabolizing enzyme neprilysin [8, 19, 22-24, 32-36, 45] . In late pregnant and nonpregnant women and rats, tachykinins induced myometrial contractions that were mainly mediated by the tachykinin NK 2 receptor, with minor participation by the NK 1 receptor [22, 24, 27-35, 37, 46, 47] . In contrast, in nonpregnant estrogen-treated BalbC mice, tachykinin-induced uterine contractions were predominantly mediated through NK 1 receptor stimulation, with NK 2 receptors playing a less important role in the response induced by NKA or NKB [36] .
The present functional studies in contrast demonstrate that contractions induced by tachykinins in longitudinally oriented uterine smooth muscle from late pregnant BalbC mice were predominantly mediated by activation of tachykinin NK 2 The data above indicate that physiological changes in the hormonal environment are capable of modifying the hierarchy of tachykinin receptor types mediating uterine contractions in the mouse. The present molecular studies show that Tacr1 mRNA levels decreased by about 11-fold at Day 17 of pregnancy compared with uteri from nonpregnant estrous, or estrogen-treated mice. These findings demonstrate, in good correlation with functional data, that the tachykinin NK 1 receptor was the predominant receptor expressed in uteri from the nonpregnant mouse and that its expression decreased markedly at late pregnancy. Tachykinin NK 2 receptor mRNA levels were slightly higher in pregnant animals, an observation that could explain the enhanced effectiveness of the NK 2 receptor-selective agonist [Lys 5 MeLeu 9 Nle 10 ]NKA(4-10), but remained essentially constant in the different hormonal stages assayed, a result identical to that previously found in the rat uterus [33] . The shift observed in functional responses in uteri from late pregnant animals appears therefore to be caused by 1) the decrease in tachykinin NK 1 receptor protein levels, 2) a slight increase of the tachykinin NK 2 receptor, and 3) a possible increase in the Ca 2ϩ sensitivity of the contractile machinery [37, 48, 49] . This is in line with the two described primary ways to modulate signal transduction through G protein-coupled receptors at the receptor level: first by structural modification of the various interactions between the receptor and other molecules that determine signal amplification and termination; and second, by a variation in the effective number of receptors available to the ligand. A third additional possibility is that there could be changes in the populations of receptor isoforms for each of the tachykinin receptor types. To this end in human nonpregnant uteri, one of us (unpublished observations) has confirmed the presence of the short NK 1 receptor, previously described by Fong et al. [50] , which is missing its 96 amino acid C-terminal tail. This isoform occurs in a ratio of 1 to 2.3 for the short NK 1 receptor to the long NK 1 receptor isoform. It is not yet known whether such a phenomenon occurs in the mouse, but these two NK 1 receptor isoforms have been shown to have altered effector systems [50] , and hence differential isoforms could provide another dimension to controlling uterine contractility.
Until recently, peripherally located tachykinins were regarded as being primarily of neuronal origin [7, 51] . The major tachykinins so expressed, including SP and NKA, are the products of the Tac1 gene and affect visceral function, including that mediated by inflammatory and immune cells; by endocrine and exocrine glands; and by vascular and visceral smooth muscle [6, 7, 9] , including uterine smooth muscle from rats, mice, and humans [19] . More recently, NKB, produced by the Tac2 (human TAC3) gene, has also been reported to be present in the periphery [22, 52] , and this peptide, and new members of the tachykinin family, including mouse HK-1 [1] , and their human orthologs [5, 8] derived from the Tac4 (human TAC4) gene are now known to be expressed in cells of non-neuronal origin, including those within the rat and human uterus, and the placenta [8, 19, 23, 52, 53] . In the present molecular studies the differential distributions and levels of expression of the three tachykinin-encoding genes are of particular interest in that they suggest 1) different cellular or regional locations (or both) of Tac1 on the one hand, and Tac2 and Tac4 on the other hand; and 2) differential modulation of these genes by hormonal and gestational status.
SP-and NKA-like immunoreactivity has been localized within uterine nerves in different species, including the mouse [15] [16] [17] [18] [19] . To our knowledge, the presence of NKB and HK-1 in these nerves has not been demonstrated. The present molecular studies show that the Tac4 gene, encoding for HK-1, was consistently expressed in both estrous and diestrous mice and on Days 5 and 17 of pregnancy. The Tac2 gene was also expressed in some, but not all, diestrous uteri, and also on Days 5 and 17 of pregnancy. Most notably, there was marked down-regulation of both Tac2 and Tac4 between early and late pregnancy. In contrast, although SP-like immunoreactivity can be observed in nonpregnant mouse uterus [19] , Tac1 transcripts were not detected in the uterus either during the estrous cycle or pregnancy. This finding is reminiscent of our recent findings with the human myometrium [24] , and may be similarly explained, because the cell bodies of the sensory neurons in which SP and NKA are synthesized before their transport to the peripheral terminals are not present in the myometrium of either species. In contrast, the products of the Tac2 and Tac4 genes in the mouse are locally produced and most likely expressed in the variety of non-neuronal cells in, or associated with, the uterine endometrium and myometrium, as reported previously for both genes in different peripheral tissues [1, 8, 22, 23, 53] .
As yet, the presence of NKB and HK-1 peptides in the uterus has not been described; however, our real-time PCR data suggest that they might be expected to be present in highest levels in diestrus and early pregnancy. Moreover, treatment of mice in vivo with the translation inhibitor cycloheximide caused a significant increase in Tac2 and Tac4 expression levels in uterine cDNA, suggesting that, under physiological conditions, these mRNAs are being translated (unpublished observations). These data strongly suggest that NKB and HK-1 peptides are locally synthesized and may play an endocrine or paracrine role (or both) in the mammalian uteri.
The tachykinin NK 3 receptor is expressed in uteri from all mammalian species so far assayed, and its expression exhibits strong variation depending on the hormonal conditions [22, 24, 32, 45] . Little is known, however, about its physiological role in the female genital tract. Our data in humans [19, 24] , rats [22, 30, 33] , and mice (present study) indicate that the NK 3 receptor may be primarily involved in functions other than mediating uterine contraction.
The present study shows that expression of the Mme gene in the mouse uteri varied markedly during the estrous cycle and during pregnancy, as also occurs in the rat and human [24, 32, 54, 55] . In rat uterus (see [19] for references) inhibitors of the enzyme neprilysin cause a marked potentiation of the uterotonic actions of tachykinins, indicating that this enzyme plays a major role in limiting these actions. In contrast, our present functional experiments did not indicate an unequivocal role for this enzyme in limiting tachykinin-induced contractions. This peptidase degrades a number of other biologically active peptides [56] , and, accordingly, may have other roles in the mouse uterus.
In conclusion, the present data show that mRNAs for Tac2 and Tac4, the genes that encode NKB and HK-1, respectively, and for the three tachykinin receptors, are expressed in the mouse uteri and their expression levels varied during the estrous cycle and throughout pregnancy. At least two of these receptors, NK 1 and NK 2 , are involved in uterine contractility, with a switch from a receptor type to another depending on the hormonal environment. The distribution of these peptides and their receptors in tissues of the female mouse reproductive tract, together with their modulation by hormonal and gestational status, as has been shown previously for rat and human, indicates a role in mammalian reproductive function.
